Suzhou Building Science

Business

Niagen Bioscience: The Science-Backed Longevity Play Building a Regulatory Fortress

With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.

Feb 3, 2026

Business

Beyond the Headlines: A Closer Look at Three Asian Penny Stocks Navigating Turbulent Markets

While global markets face headwinds, Asia's smaller-cap stocks offer a unique lens into regional resilience and risk. We analyze the financial health and prospects of Huili Resources, Guangxi Fenglin Wood, and Suzhou Institute of Building Science.

Feb 5, 2026

Business

Johnson Controls Kicks Off Fiscal 2026 with Record Orders, Raises Full-Year Outlook on Data Center and Life Sciences Surge

Johnson Controls International (JCI) reported a robust first quarter, exceeding expectations and raising its full-year earnings guidance. The company cited record order growth, particularly in data center and life sciences segments, alongside significant margin expansion. Executives highlighted a record $18 billion backlog but noted timing challenges for near-term revenue conversion.

Feb 5, 2026

Business

IDEX Beats Q4 Expectations on Surging Health & Science Demand, Charts Cautious 2026 Course

IDEX Corporation capped off fiscal 2025 with stronger-than-anticipated fourth-quarter results, propelled by a record-setting order surge in its Health & Science Technologies unit linked to data center and AI infrastructure. While management expressed confidence in its strategic evolution, it offered a measured outlook for the coming year amid a mixed industrial landscape.

Feb 5, 2026

Business

AbbVie Surpasses Expectations in 2025, Powered by Skyrizi, Rinvoq, and Neuroscience Amid Humira Transition

AbbVie reported record full-year revenue and earnings for 2025, significantly exceeding its initial guidance. The company's growth was driven by its immunology blockbusters Skyrizi and Rinvoq, a rapidly expanding neuroscience portfolio, and strategic acquisitions, successfully offsetting the steep decline of its former top-seller Humira.

Feb 5, 2026

Business

Healthpeak Navigates Life Science Headwinds with Strong Outpatient and Senior Housing Performance; Announces Senior Housing REIT Spin-Off

Healthpeak Properties reported resilient fourth-quarter results, driven by strength in its Outpatient Medical and Senior Housing segments, which helped counter a prolonged downturn in Life Science. The company announced a major portfolio repositioning, including a strategic lab acquisition and plans to spin off its Senior Housing portfolio into a new publicly traded REIT, Janus Living.

Feb 4, 2026

Business

Achieve Life Sciences Nears FDA Verdict on Smoking Cessation Drug, Fueling Investor Optimism

With a key FDA decision on its non-nicotine therapy cytisinicline expected by mid-2026, Achieve Life Sciences (ACHV) is drawing bullish attention for its potential to address a massive unmet need in smoking cessation and tap into a newly opened market void.

Feb 3, 2026

Business

RoundTable Healthcare Partners Acquires Colorescience, Bolstering Portfolio with Fast-Growing Skincare Brand

Private equity firm RoundTable Healthcare Partners has acquired the dermatologist-trusted skincare and sun protection brand Colorescience from 1315 Capital, as the company's annual sales approach the $100 million mark.

Feb 2, 2026

Business

Twist Bioscience Powers Ahead: Q1 2026 Revenue Jumps 17%, Fueled by AI-Driven Discovery Boom

Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.

Feb 2, 2026

Business

Eli Lilly Commits $3.5 Billion to Pennsylvania, Creating 850 Jobs in Major Life Sciences Push

Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.

Jan 30, 2026

Business

Brad Jacobs Bets Big on Building Materials: Can QXO's Roll-Up Strategy Deliver?

With a $1 billion war chest and a veteran industrialist at the helm, QXO, Inc. is embarking on an ambitious mission to consolidate the fragmented U.S. building products distribution market. We examine the bullish case, the risks, and what it means for investors.

Feb 5, 2026

Business

Twist Bioscience Raises Revenue Outlook on Surging AI-Driven Demand, Spotlighting Growth and Volatility

Synthetic biology firm Twist Bioscience has lifted its full-year revenue guidance, citing robust demand for its AI-powered DNA and protein platforms. The announcement, coupled with strategic equity grants to new hires, underscores the company's aggressive push to capitalize on the booming intersection of AI and biotech, even as its long-term stock performance reveals underlying volatility.

Feb 5, 2026

Business

Vita Life Sciences Shares Surge 18%: Strong Financials Fuel Investor Confidence

Vita Life Sciences Ltd (ASX:VLS) has seen its share price climb 18% over the past quarter. Analysts point to the company's robust Return on Equity and consistent earnings growth as key drivers behind the rally, outperforming broader industry benchmarks.

Feb 4, 2026

Business

Barclays Takes Cautious Stance on Building Products as Ferguson Prepares Q4 Report

Barclays raises price target on Ferguson (FERG) ahead of earnings, but advises selectivity in the building products sector amid mixed demand and policy uncertainty.

Feb 4, 2026

Business

Niagen Bioscience (NAGE) in Focus: Can Its NAD+ IP and Pending Catalysts Justify a Higher Valuation?

After recent share price declines, Niagen Bioscience is drawing renewed investor scrutiny. The biotech firm's valuation story hinges on its proprietary NAD+ technology, upcoming B2B product launches, and critical clinical data readouts expected later this year.

Feb 4, 2026

US

Morning Briefing: U.K. Launches Probe into Epstein Document Leak Claims, Netflix Faces Political Heat, and Science Funding Rescued

A former British minister steps down amid an investigation into leaked documents linked to Jeffrey Epstein. Meanwhile, U.S. lawmakers clash with Netflix over 'woke' content allegations, and Congress reverses course on proposed science budget cuts.

Feb 4, 2026

Business

Integra LifeSciences Shareholders Face Steep Losses as Stock Plummets 84% Over Five Years

Long-term investors in Integra LifeSciences Holdings have seen their holdings decimated, with the stock's dramatic decline raising questions about the medical device maker's turnaround prospects and broader sector challenges.

Feb 4, 2026

Business

Twist Bioscience's Rally Raises Valuation Questions: Is the Biotech Stock Running Ahead of Itself?

Twist Bioscience shares have surged over 40% in the past month, reigniting investor debate. While short-term momentum is strong, the stock's long-term performance and a significant gap between its market price and some fair value estimates present a complex picture for the synthetic biology firm.

Feb 4, 2026

Business

Minerva Neurosciences Charts Final Path for Schizophrenia Drug Targeting Debilitating 'Negative Symptoms'

In a pivotal virtual briefing, Minerva Neurosciences detailed its confirmatory Phase 3 trial design for roluperidone, a potential first-in-class therapy for the persistent and disabling negative symptoms of schizophrenia, with top-line results expected by late 2027.

Feb 4, 2026

Business

Ashland Navigates Market Headwinds: Life Sciences Shines Amidst Coatings Slump, Full-Year Outlook Adjusted

Specialty chemicals leader Ashland reports a mixed Q1 FY2026, with resilient performance in Life Sciences and Personal Care offsetting continued softness in coatings and construction. The company revises its full-year EBITDA guidance, citing operational delays at a key facility and weather-related disruptions.

Feb 3, 2026